Locally Advanced or Metastatic Solid Tumors Clinical Trial
Official title:
A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter, open label, sequential-cohort, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose (MTD）, if any, Recommended Phase II Doses (RP2Ds) and regimen of CS3006. The study is composed of two parts: Part 1 for dose escalation and Part 2 for dose expansion.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04564417 -
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04511845 -
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
|
Phase 1 | |
| Active, not recruiting |
NCT04128423 -
Study of AMV564 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05012618 -
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
|
Phase 1 | |
| Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05137275 -
Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT01021748 -
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
|
Phase 1 | |
| Completed |
NCT01713036 -
Oral Bioavailability and Mass Balance Trial With Pimasertib
|
Phase 1 | |
| Recruiting |
NCT05116709 -
Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05102214 -
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03478995 -
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06293651 -
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06328439 -
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05830539 -
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05205109 -
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05360381 -
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03150810 -
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05957471 -
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03565991 -
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06244992 -
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 |